ABSTRACT
ABSTRACT During the state of immune vulnerability in hematopoietic stem cell transplantation (HSCT), the patient has an increased risk of developing a vast number of complications, including severe problems in the oral cavity. These situations require professional oral care to act in the diagnosis and treatment of these conditions, as well as to develop prevention protocols to minimize patient's complications. Oral mucositis, opportunistic infections, bleeding, specific microbiota, taste, and salivary alterations are complications that can occur during HSCT and interfere with various aspects, such as pain control, oral intake, nutrition, bacteremia and sepsis, days of hospitalization and morbidity. Several guidelines have been published to address the role of professional oral care during the HSCT, we describe a consensus regarding these recommendations.
ABSTRACT
O tumor marrom é uma lesão intraóssea benigna focal associada ao hiperparatireoidismo. Ocorre preferencialmente em ossos longos, costelas e pelve, porém, eventualmente pode acometer maxila e mandíbula. O prognóstico está associado à causa e ao tipo de hiperparatireoidismo, com isso é de grande importância o diagnóstico precoce para que seja estabelecido o quanto antes a terapêutica adequada. Apesar destas lesões serem raras nos ossos gnáticos e quando presentes estarem associadas principalmente ao hi per pa ratireoidismo primário e em mulheres com mais de 50 anos de idade, propusemos relatar um caso de tumor marrom secundário do hiperparatireoidismo em paciente do gênero masculino e de 36 anos de idade.
The brown tumor is a focal benign intraosseous lesion associated with hyperparathyroidism. Preferably occurs in long bones, ribs and pelvis, however, may eventually affect the jaws. The prognosis is associated with the cause and type of hyperparathyroidism, with that It is very important for an early diagnosis so it can soon be established an appropriate therapy. Although these are rare injuries on the gnathic bones and when present are mainly associated with primary hyperparathyroidism and in women over 50 years old, we proposed to report a case of secondary hyperparathyroidism brown tumor in a 36 years old male patient.
ABSTRACT
No tratamento das leucemias é utilizada a quimioterapia, que apresenta vários efeitos colaterais. A mucosite bucal é a principal causa de dor durante a quimioterapia e a complicação mais comum dotratamento para neoplasias hematológicas. Esse estudo teve o objetivo de avaliar o uso do laser debaixa intensidade e da clorexidina 0,12% no tratamento da mucosite bucal decorrente de quimioterapiaem crianças leucêmicas. A amostra foi constituída por 10 crianças (Grupo Experimental) com leucemia aguda submetidas à quimioterapia e portadoras de mucosite bucal Graus I, II ou III, atendidas noHospital Araújo Jorge da Associação de Combate ao Câncer em Goiás. Também fazia parte da amostra, dados de 24 prontuários de pacientes infantis com leucemia aguda, tratados no mesmo hospital, que apresentaram mucosite bucal como intercorrência do tratamento de quimioterapia. Os pacientes do Grupo Experimental foram aleatoriamente distribuídos para receber o tratamento 1 (clorexidina 0,12%) ou 2 (laser). A presença e o grau de mucosite eram avaliados pelo mesmo examinador. Para comparação, os dados de prontuários de pacientes previamente tratados foram registrados, sendo que para estes, era utilizado apenas o tratamento sintomático da mucosite bucal. Os registros, da mesma forma, eram anotados quanto à presença e grau de mucosite. A mucosite bucal foi menos freqüente e teve menor tempo de duração no grupo que recebeu tratamento (clorexidina ou laser) do que no gruposem tratamento. A associação das várias formas de tratamento (higiene bucal, clorexidina e laser) leva à redução do número de episódios de mucosite bem como menor duração das lesões
Chemotherapy, which presents several side effects, is used in the management of leukemia. Oral mucositis is the main cause of pain during chemotherapy and is the most common complication in the management of hematological cancer. The aim of the current study was to investigate the utilization of the low-energy laser and the use of chlorexidine 0,12% in the management of oral mucositis due to chemotherapy in children with leukemia. The study group was composed of 10 children with acute leukemia, who developed oral mucositis grade I, II, or III, and who underwent chemotherapy at the Araújo Jorge Hospital at the Combat Cancer Association of Goias. 24 case records of infant patients with acute leukemia, who were managed at the already mentioned hospital, and who developed oral mucositis as intercurrence of chemotherapy, were also included. The patients in the Study Group were randomized tobe treated with 1 (chlorexidine 0,12%) or 2 (laser). The presence and the degree of mucositis being evaluated by the same examiner. For comparison, data in the charts of patients previously treated were registered. For these patients, just the symptomatic treatment of the oral mucositis was used. The data about the presence and degree of mucositis were equally logged. Oral mucositis was less frequent and had a shorter period of duration in the treated group (chlorexidine or laser) than in the untreated group. The association of various forms of treatment (oral hygiene, chlorhexidine and laser) decreases the number of mucositis occurrences and shortens duration of the lesions